Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03841084
Other study ID # ANZIC-RC/DP001
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 18, 2019
Est. completion date January 31, 2024

Study information

Verified date January 2024
Source Australian and New Zealand Intensive Care Research Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine in patients requiring venoarterial (V-A) ECMO, whether the use of a conservative as compared with liberal oxygen strategy, results in a greater number of ICU-free days at day 28.


Description:

Extracorporeal membrane oxygenation (ECMO) can be a lifesaving procedure for the sickest patients in the Intensive Care Unit (ICU) who are at risk of death from severe cardiac and respiratory failure. ECMO is a device which pumps blood out of the body and returns it back after adding oxygen and removing carbon dioxide. While potentially life-saving, ECMO is associated with high use of critical care resources and increased risk of adverse outcomes in survivors. The BLENDER Trial is a multicentre trial in ECMO patients to determine whether a conservative oxygen strategy during ECMO reduces ICU length of stay and improves patient outcomes compared to a liberal oxygen strategy. Both strategies are currently standard practice worldwide, however, there is no consensus to which strategy is better for our patients. This trial aims to utilise an existing intensive care registry and will recruit 300 patients with life threatening acute cardiac or respiratory failure. If the BLENDER Trial confirms that one oxygen management strategy is more effective than the other, its findings may improve the lives of critically ill Australians and inform clinical practice worldwide.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 300
Est. completion date January 31, 2024
Est. primary completion date July 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: • Patients =18 years who are commenced on V-A ECMO for severe cardiac, or following refractory cardiac arrest. Exclusion Criteria: - Greater than 6 hours have elapsed from the time of initiation of ECMO to randomisation - Patients who are suspected or confirmed to be pregnant - Where an indication exists for a specific oxygen target as part of clinical care (e.g. carbon monoxide poisoning) - Patients who are already enrolled in another oxygen titration study (unless agreed by study committees) - Patients not willing to receive blood products (e.g. Jehovah's Witness) - Where the treating physician deems the study is not in the patient's best interest

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxygen
Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit. Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit

Locations

Country Name City State
Australia Alfred Health Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Australian and New Zealand Intensive Care Research Centre

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Other ECMO circuit life number of hours that each circuit was in use day 28
Primary The primary outcome will be the number of alive and ICU-free days to day 28. ICU free days are defined as the total number of days (or part days) being free of ICU between randomisation and day 28, with the exception that all patients who die by day 28 will be defined as having zero ICU free days. at day 28
Secondary Hospital mortality Mortality rates of patients that day in hospital from randomisation to day 28 at day 28
Secondary ICU mortality Mortality rates of patients that day in ICU from randomisation to day 28 at day 28
Secondary ICU length of stay Number of hours spent in ICU from randomisation up to day 28 at day 28
Secondary Duration of mechanical ventilation Number of hours requiring mechanical ventilation from randomisation to day 28 at day 28
Secondary Disability World Health Organisation's Disability Assessment Schedule 2.0 12L 6 and 12 months
Secondary Health-related quality of life at six and twelve months using the EQ5D-5L Euro Qol Group Health Survey (EQ-5D-5L) Measuring quality of life which looks at five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. 6 and 12 months
Secondary Psychological function at six and twelve months Measured using a trained, blinded assessor via telephone interview 6 months & 12 months
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness